Current Clinical Experience with Nevirapine for HIV Infection
- 1 January 1996
- book chapter
- Published by Springer Nature
- Vol. 394, 299-304
- https://doi.org/10.1007/978-1-4757-9209-6_27
Abstract
Nevirapine is a non-nucleoside reverse transcriptase inhibitor specific for HIV-1.1,2 This review will focus on some clinically important aspects of the pharmacology and virology of nevirapine, as well as adverse events and the results of some completed clinical studies.This publication has 9 references indexed in Scilit:
- 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 1992
- Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.Proceedings of the National Academy of Sciences, 1991
- Inhibition of Human Immunodeficiency Virus Type I (HIV-I) Replication by the Dipyridodiazepinone BI-RG-587The Journal of Infectious Diseases, 1991
- BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudineAntimicrobial Agents and Chemotherapy, 1991
- Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase InhibitorScience, 1990